Literature DB >> 25117713

MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state.

Yulin Li1, Peter S Choi1, Stephanie C Casey1, David L Dill2, Dean W Felsher3.   

Abstract

The MYC oncogene regulates gene expression through multiple mechanisms, and its overexpression culminates in tumorigenesis. MYC inactivation reverses turmorigenesis through the loss of distinguishing features of cancer, including autonomous proliferation and survival. Here we report that MYC via miR-17-92 maintains a neoplastic state through the suppression of chromatin regulatory genes Sin3b, Hbp1, Suv420h1, and Btg1, as well as the apoptosis regulator Bim. The enforced expression of miR-17-92 prevents MYC suppression from inducing proliferative arrest, senescence, and apoptosis and abrogates sustained tumor regression. Knockdown of the five miR-17-92 target genes blocks senescence and apoptosis while it modestly delays proliferative arrest, thus partially recapitulating miR-17-92 function. We conclude that MYC, via miR-17-92, maintains a neoplastic state by suppressing specific target genes.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25117713      PMCID: PMC4191901          DOI: 10.1016/j.ccr.2014.06.014

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  52 in total

1.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Authors:  M Gossen; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

2.  Transcriptional amplification in tumor cells with elevated c-Myc.

Authors:  Charles Y Lin; Jakob Lovén; Peter B Rahl; Ronald M Paranal; Christopher B Burge; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2012-09-28       Impact factor: 41.582

Review 3.  MYC on the path to cancer.

Authors:  Chi V Dang
Journal:  Cell       Date:  2012-03-30       Impact factor: 41.582

4.  Reversible tumorigenesis by MYC in hematopoietic lineages.

Authors:  D W Felsher; J M Bishop
Journal:  Mol Cell       Date:  1999-08       Impact factor: 17.970

5.  c-Myc-regulated microRNAs modulate E2F1 expression.

Authors:  Kathryn A O'Donnell; Erik A Wentzel; Karen I Zeller; Chi V Dang; Joshua T Mendell
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

6.  A microRNA polycistron as a potential human oncogene.

Authors:  Lin He; J Michael Thomson; Michael T Hemann; Eva Hernando-Monge; David Mu; Summer Goodson; Scott Powers; Carlos Cordon-Cardo; Scott W Lowe; Gregory J Hannon; Scott M Hammond
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

7.  Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas.

Authors:  Ping Mu; Yoon-Chi Han; Doron Betel; Evelyn Yao; Massimo Squatrito; Paul Ogrodowski; Elisa de Stanchina; Aleco D'Andrea; Chris Sander; Andrea Ventura
Journal:  Genes Dev       Date:  2009-12-15       Impact factor: 11.361

8.  HBP1 and Mad1 repressors bind the Sin3 corepressor PAH2 domain with opposite helical orientations.

Authors:  Kurt A Swanson; Paul S Knoepfler; Kai Huang; Richard S Kang; Shaun M Cowley; Carol D Laherty; Robert N Eisenman; Ishwar Radhakrishnan
Journal:  Nat Struct Mol Biol       Date:  2004-07-04       Impact factor: 15.369

9.  Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations.

Authors:  Asa Karlsson; Sylvie Giuriato; Flora Tang; Jingly Fung-Weier; Göran Levan; Dean W Felsher
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113

Review 10.  Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.

Authors:  Marc Ladanyi; William Pao
Journal:  Mod Pathol       Date:  2008-05       Impact factor: 7.842

View more
  91 in total

1.  ALK positively regulates MYCN activity through repression of HBP1 expression.

Authors:  Shana Claeys; Geertrui Denecker; Kaat Durinck; Bieke Decaesteker; Liselot M Mus; Siebe Loontiens; Suzanne Vanhauwaert; Kristina Althoff; Caroline Wigerup; Daniel Bexell; Emmy Dolman; Kai-Oliver Henrich; Lea Wehrmann; Ellen M Westerhout; Jean-Baptiste Demoulin; Candy Kumps; Tom Van Maerken; Genevieve Laureys; Christophe Van Neste; Bram De Wilde; Olivier De Wever; Frank Westermann; Rogier Versteeg; Jan J Molenaar; Sven Påhlman; Johannes H Schulte; Katleen De Preter; Frank Speleman
Journal:  Oncogene       Date:  2018-12-11       Impact factor: 9.867

2.  c-Myc plays a key role in TADs-induced apoptosis and cell cycle arrest in human hepatocellular carcinoma cells.

Authors:  Dongdong Zhang; Junpeng Qi; Rui Liu; Bingling Dai; Weina Ma; Yingzhuan Zhan; Yanmin Zhang
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

Review 3.  The potential of targeting Sin3B and its associated complexes for cancer therapy.

Authors:  David J Cantor; Gregory David
Journal:  Expert Opin Ther Targets       Date:  2017-10-09       Impact factor: 6.902

4.  Methods of Expression, Purification, and Preparation of the c-Myc b-HLH-LZ for Its Biophysical Characterization.

Authors:  Patrick Delattre; Martin Montagne; Pierre Lavigne
Journal:  Methods Mol Biol       Date:  2021

5.  Growth hormone deficiency, aortic dilation, and neurocognitive issues in Feingold syndrome 2.

Authors:  Michael Muriello; Alexander Y Kim; Krista Sondergaard Schatz; Natalie Beck; Meral Gunay-Aygun; Julie E Hoover-Fong
Journal:  Am J Med Genet A       Date:  2019-01-23       Impact factor: 2.802

6.  Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy.

Authors:  Ginés Luengo-Gil; Elena García-Martínez; Asunción Chaves-Benito; Pablo Conesa-Zamora; Esther Navarro-Manzano; Enrique González-Billalabeitia; Elisa García-Garre; Alberto Martínez-Carrasco; Vicente Vicente; Francisco Ayala de la Peña
Journal:  Cell Oncol (Dordr)       Date:  2019-05-21       Impact factor: 6.730

7.  miR-17-92 explains MYC oncogene addiction.

Authors:  Yulin Li; Stephanie C Casey; Peter S Choi; Dean W Felsher
Journal:  Mol Cell Oncol       Date:  2014-12-31

8.  miRNA target identification and prediction as a function of time in gene expression data.

Authors:  Pranas Grigaitis; Vytaute Starkuviene; Ursula Rost; Andrius Serva; Pascal Pucholt; Ursula Kummer
Journal:  RNA Biol       Date:  2020-04-22       Impact factor: 4.652

9.  MicroRNA 675 cooperates PKM2 to aggravate progression of human liver cancer stem cells induced from embryonic stem cells.

Authors:  Yuxin Yang; Qiuyu Meng; Chen Wang; Xiaonan Li; Yanan Lu; Xiaoru Xin; Qidi Zheng; Dongdong Lu
Journal:  J Mol Med (Berl)       Date:  2018-08-23       Impact factor: 4.599

10.  Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.

Authors:  Baohua Sun; Bhavin Shah; Warren Fiskus; Jun Qi; Kimal Rajapakshe; Cristian Coarfa; Li Li; Santhana G T Devaraj; Sunil Sharma; Liang Zhang; Michael L Wang; Dyana T Saenz; Stephanie Krieger; James E Bradner; Kapil N Bhalla
Journal:  Blood       Date:  2015-08-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.